 Home > Biochemistry News > Biotechnology News > Bring 91% of patients back to normal triglycerides and innovative oligonucleotide therapy advances to phase 3 clinical trials

Bring 91% of patients back to normal triglycerides and innovative oligonucleotide therapy advances to phase 3 clinical trials

 Last Update: 2021-11-14
 Source: Internet
 Author: User

Tags

etodolac 200 mg

chronic airways disease

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On November 2, 2021, Ionis Pharmaceuticals announced the initiation of a pivotal Phase 3 clinical trial of the antisense oligonucleotide (ASO) therapy olezarsen under development.

ASO therapy targets mRNA and relies on RNase H to degrade the complex produced by the combination of ASO and mRNA, thereby inhibiting the production of pathogenic proteins

A previous phase 2 clinical trial reached its primary and key secondary endpoints.

▲Phase 2 clinical results of Olezarsen (AKCEA-APOCIII-LRx) (picture source: Ionis official website)

The ongoing Phase 3 clinical trial will enroll more than 1,500 patients, and the primary endpoint is the percentage change in patients' fasting triglyceride levels from baseline at the 6th month of treatment

Reference materials:

[1] Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.